{"id":44274,"date":"2024-10-21T12:03:00","date_gmt":"2024-10-21T10:03:00","guid":{"rendered":"https:\/\/kapitalpartner.dk\/?p=44274"},"modified":"2024-10-24T12:03:57","modified_gmt":"2024-10-24T10:03:57","slug":"biosergen-skyrockets-145-and-virogates-enters-into-distribution-agreement","status":"publish","type":"post","link":"https:\/\/kapitalpartner.dk\/en\/biosergen-skyrockets-145-and-virogates-enters-into-distribution-agreement\/","title":{"rendered":"Biosergen skyrockets 145% and ViroGates enters into distribution agreement"},"content":{"rendered":"\n

NORDIC | BIOTECH & HEALTHCARE<\/strong> Your insights into listed Danish & Nordic biotech & healthcare stocks.<\/em><\/p>\n\n\n\n

In the past week, the Nordic biotech and healthcare stocks rose 0.5% with the Danish ones rising 8%. Most notably, Biosergen rose 145% with very strong momentum throughout the week. Further, Virogates entered into a distribution agreement, Genmab beat sales expectations, Acarix secured yet another order, and Cessatech announced recruitment of 75 patients in their Paediatric Study 0202.<\/strong><\/p>\n\n\n\n

Only 12 of the 22 Danish biotech companies had a positive share price development in the past week and 11 companies have had a positive share price performance year-to-date Obesity continues to drive the best performances with Gubra, Zealand Pharma, and Pila Pharma having strong YTD performance.<\/strong> Five <\/strong><\/span>Danish healthcare stocks with +100% YTD return.<\/strong><\/p>\n\n\n\n

\n
Register for the Nordic I Impact newsletter here.<\/strong><\/a><\/div>\n<\/div>\n\n\n\n

<\/p>\n\n\n\n

Danish company news<\/strong><\/p>\n\n\n\n

Acarix AB<\/a><\/strong><\/p>\n\n\n\n

Acarix Secures Expansion Order from Existing CADScor System Customer (Link<\/a>)<\/p>\n\n\n\n

Ascendis Pharma<\/a><\/strong><\/p>\n\n\n\n

No news the past wee<\/em>k<\/em><\/em><\/em><\/p>\n\n\n\n

Biosergen<\/a><\/strong><\/p>\n\n\n\n

No news the past wee<\/em>k<\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Cessatech<\/a><\/strong><\/p>\n\n\n\n

Cessatech announces that recruitment has today reached the halfway point for patient recruitment with 75 included patients in the Paediatric Study 0202<\/em><\/em><\/em><\/em> (Link<\/a>)<\/p>\n\n\n\n

CS Medica<\/a><\/strong><\/p>\n\n\n\n

No news the past wee<\/em>k<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Curasight<\/a><\/strong><\/p>\n\n\n\n

No news the past wee<\/em>k<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

DanCann Pharma<\/a><\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Evaxion Biotech<\/a><\/strong><\/p>\n\n\n\n

No news the past wee<\/em>k<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

ExpreS2ion<\/a><\/strong><\/p>\n\n\n\n

ExpreS2ion and Serum Institute of India have entered in a term sheet regarding proposed development and commercialization of novel malaria vaccines (Link<\/a>)<\/p>\n\n\n\n

Fluoguide<\/a><\/strong><\/p>\n\n\n\n

No news the past wee<\/em>k<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Genmab<\/a><\/strong><\/p>\n\n\n\n

Genmab Announces Net Sales of DARZALEX\u00ae (daratumumab) for Third Quarter of 2024 (Link<\/a>)<\/p>\n\n\n\n

Jyske Bank lowered their price target from DKK 2,600 to DKK 2,400, and UBS to DKK 2,700 from DKK 2,850. <\/p>\n\n\n\n

Gubra<\/a><\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Initiator Pharma<\/a><\/strong><\/p>\n\n\n\n

The decision to issue new shares and conduct share buyback, as well as the sale of shares in connection with the long-term incentive program for 2023<\/em><\/em><\/em><\/em> (Link<\/a>)<\/p>\n\n\n\n

IO Biotech<\/a><\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Pila Pharma<\/a><\/strong><\/p>\n\n\n\n

PILA PHARMA INFORMS OF OPTIMIZATION CHANGES TO TRIAL PLAN<\/em><\/em><\/em><\/em> (Link<\/a>)<\/p>\n\n\n\n

Saniona<\/a><\/strong><\/p>\n\n\n\n

Saniona Ion Channel Research Collaboration with Boehringer Ingelheim Reaches Milestone (Link<\/a>)<\/p>\n\n\n\n

Scandion Oncology<\/a><\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

SynAct Pharma<\/a><\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

ViroGates<\/a><\/strong><\/p>\n\n\n\n

ViroGates announces a distribution agreement with suPAR Health and a directed issue of shares to suPAR Remedy LLC<\/em><\/em> (Link<\/a>)<\/p>\n\n\n\n

Zealand Pharma<\/a><\/strong><\/p>\n\n\n\n

Bank of America initiated a price target of DKK 1,100, while the current stock price is DKK 805<\/p>\n\n\n\n

Y-mAbs Therapeutic<\/a><\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

2cureX<\/a><\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Share price development – Danish stocks<\/strong><\/p>\n\n\n\n

On average, the Danish biotech and healthcare stocks delivered a return of 8% driven by Biosergen<\/a><\/strong> with a 145% return. Biosergen<\/a> <\/strong>delivered very strong momentum throughout the week with daily double-digit increases although the company did not report any news. ViroGates<\/a><\/strong> entered a distribution agreement with suPAR Health in the U.S. as well as a directed issue of MDKK 8.2 with suPAR Remedy at a 10% premium. Genmab<\/a><\/strong> beat expectations of Darzalex sales by a couple of percentages, while Acarix<\/a><\/strong> <\/strong><\/a><\/span>got yet another new order. Moreover, Cessatech<\/a><\/strong> announced the recruitment of 75 patients in their Paediatric Study 0202 being halfway to 150 patients. Finally, Evaxion<\/a><\/strong> entered into a term sheet regarding the development of malaria vaccines together with the Serum Institute of India.<\/p>\n\n\n\n

Gubra<\/a><\/strong> continues to be the best-performing stock year-to-date with a return of 242%. Pila Pharma<\/a><\/strong>, Zealand Pharma<\/a><\/strong>, Cessatech<\/a>,<\/strong> and Y-mAbs Therapeutic<\/a><\/strong> have also generated returns of over 100% in 2024.<\/p>\n\n\n\n

Investment case for Curasight<\/a><\/strong><\/p>\n\n\n\n

Overview of share price development the past week, year-to-date, and the last twelve month<\/strong><\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

Nordic Biotech & Healthcare Developments<\/mark><\/strong><\/p>\n\n\n\n

In the past week, the all-Nordic index Kapital Partner Nordic Healthcare Index (KPHC)<\/strong> rose 0.5% to 66,43. The index has had a strong performance since the beginning of October last year and it has now not only surpassed the KPNGX index but it has also joined the larger indices regarding performance. In the past 12 months, the KPHC index has thus had higher volatility but is now among the same performance as C25 and S30 – far better than the other Nordic growth exchange stocks.<\/p>\n\n\n\n

The Nordic healthcare stocks (KPHC) vs. C25, S30, and KPNGX the past year<\/strong><\/p>\n\n\n\n

\"\"
The KPHC index includes all Nordic healthcare stocks. This means both Novo Nordisk and Genmab as well as Curasight.<\/sup><\/figcaption><\/figure>\n\n\n\n

The top three best-performing stocks in the past week<\/strong><\/p>\n\n\n\n

Biosergen<\/a> (145%)<\/strong> specializes in the research and development of various drugs. The product portfolio includes, for example, the company’s product BSG005, an antifungal drug in the clinical phase. In addition to the main business, the company also offers service and related ancillary services. Operations are conducted in Norway.<\/p>\n\n\n\n

Alteco Medical AB<\/a> (75%)<\/strong> is active in medical technology and provides an extracorporeal blood purification product that removes endotoxin (lipopolysaccharide, LPS) from the patient’s bloodstream. The product is used as an adjunctive therapy in sepsis to treat endotoxemia (high levels of endotoxin). This can help to stabilize the patient in various acute situations. Endotoxemia is common in sepsis, which is a life-threatening condition and one of the most common causes of death in modern intensive care.<\/p>\n\n\n\n

PharmaLundensis AB<\/a> (58%)<\/strong> specializes in the development of medical devices. The product portfolio is broad and includes products for male infertility and individually tailored fertility treatments. Research and development is conducted via its own technological platform that analyzes sperm quality, which is further used for medical data and potential fertilization.<\/p>\n\n\n\n

Resources: Refinitiv Eikon, Cision, Nordnet & company websites<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"

NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks. In the past week, the Nordic biotech and healthcare stocks rose 0.5% with the Danish ones rising 8%. Most notably, Biosergen rose 145% with very strong momentum throughout the week. Further, Virogates entered into a distribution agreement, Genmab beat sales […]<\/p>\n","protected":false},"author":11,"featured_media":43132,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[9,29,165,205,163],"tags":[],"class_list":["post-44274","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-en-investeringscases","category-investeringscases","category-investment-cases","category-news","category-sector-cases"],"acf":[],"yoast_head":"\nBiosergen skyrockets 145% and ViroGates enters into distribution agreement | Kapital Partner A\/S<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/kapitalpartner.dk\/en\/biosergen-skyrockets-145-and-virogates-enters-into-distribution-agreement\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biosergen skyrockets 145% and ViroGates enters into distribution agreement | Kapital Partner A\/S\" \/>\n<meta property=\"og:description\" content=\"NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks. In the past week, the Nordic biotech and healthcare stocks rose 0.5% with the Danish ones rising 8%. Most notably, Biosergen rose 145% with very strong momentum throughout the week. Further, Virogates entered into a distribution agreement, Genmab beat sales […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/kapitalpartner.dk\/en\/biosergen-skyrockets-145-and-virogates-enters-into-distribution-agreement\/\" \/>\n<meta property=\"og:site_name\" content=\"Kapital Partner A\/S\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/kapitalpartner\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-21T10:03:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-24T10:03:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"724\" \/>\n\t<meta property=\"og:image:height\" content=\"418\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Anders S\u00f8ndergaard\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@KapitalPartner\" \/>\n<meta name=\"twitter:site\" content=\"@KapitalPartner\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Anders S\u00f8ndergaard\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/biosergen-skyrockets-145-and-virogates-enters-into-distribution-agreement\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/biosergen-skyrockets-145-and-virogates-enters-into-distribution-agreement\/\"},\"author\":{\"name\":\"Anders S\u00f8ndergaard\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed\"},\"headline\":\"Biosergen skyrockets 145% and ViroGates enters into distribution agreement\",\"datePublished\":\"2024-10-21T10:03:00+00:00\",\"dateModified\":\"2024-10-24T10:03:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/biosergen-skyrockets-145-and-virogates-enters-into-distribution-agreement\/\"},\"wordCount\":882,\"publisher\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/biosergen-skyrockets-145-and-virogates-enters-into-distribution-agreement\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg\",\"articleSection\":[\"All investment Cases\",\"Investeringscases\",\"Investment cases\",\"News\",\"Sector cases\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/biosergen-skyrockets-145-and-virogates-enters-into-distribution-agreement\/\",\"url\":\"https:\/\/kapitalpartner.dk\/en\/biosergen-skyrockets-145-and-virogates-enters-into-distribution-agreement\/\",\"name\":\"Biosergen skyrockets 145% and ViroGates enters into distribution agreement | Kapital Partner A\/S\",\"isPartOf\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/biosergen-skyrockets-145-and-virogates-enters-into-distribution-agreement\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/biosergen-skyrockets-145-and-virogates-enters-into-distribution-agreement\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg\",\"datePublished\":\"2024-10-21T10:03:00+00:00\",\"dateModified\":\"2024-10-24T10:03:57+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/biosergen-skyrockets-145-and-virogates-enters-into-distribution-agreement\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/kapitalpartner.dk\/en\/biosergen-skyrockets-145-and-virogates-enters-into-distribution-agreement\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/biosergen-skyrockets-145-and-virogates-enters-into-distribution-agreement\/#primaryimage\",\"url\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg\",\"contentUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg\",\"width\":724,\"height\":418},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/biosergen-skyrockets-145-and-virogates-enters-into-distribution-agreement\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/kapitalpartner.dk\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"All investment Cases\",\"item\":\"https:\/\/kapitalpartner.dk\/en\/category\/investment-cases\/en-investeringscases\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Biosergen skyrockets 145% and ViroGates enters into distribution agreement\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/kapitalpartner.dk\/#website\",\"url\":\"https:\/\/kapitalpartner.dk\/\",\"name\":\"Kapital Partner A\/S\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/kapitalpartner.dk\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\",\"name\":\"Kapital Partner A\/S\",\"url\":\"https:\/\/kapitalpartner.dk\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png\",\"contentUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png\",\"width\":496,\"height\":432,\"caption\":\"Kapital Partner A\/S\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/kapitalpartner\",\"https:\/\/x.com\/KapitalPartner\",\"https:\/\/www.linkedin.com\/company\/10438322\",\"https:\/\/www.youtube.com\/channel\/UCODuY5PE_fxmp2nSSsq3l3w\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed\",\"name\":\"Anders S\u00f8ndergaard\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g\",\"caption\":\"Anders S\u00f8ndergaard\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Biosergen skyrockets 145% and ViroGates enters into distribution agreement | Kapital Partner A\/S","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/kapitalpartner.dk\/en\/biosergen-skyrockets-145-and-virogates-enters-into-distribution-agreement\/","og_locale":"en_US","og_type":"article","og_title":"Biosergen skyrockets 145% and ViroGates enters into distribution agreement | Kapital Partner A\/S","og_description":"NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks. In the past week, the Nordic biotech and healthcare stocks rose 0.5% with the Danish ones rising 8%. Most notably, Biosergen rose 145% with very strong momentum throughout the week. Further, Virogates entered into a distribution agreement, Genmab beat sales […]","og_url":"https:\/\/kapitalpartner.dk\/en\/biosergen-skyrockets-145-and-virogates-enters-into-distribution-agreement\/","og_site_name":"Kapital Partner A\/S","article_publisher":"https:\/\/www.facebook.com\/kapitalpartner","article_published_time":"2024-10-21T10:03:00+00:00","article_modified_time":"2024-10-24T10:03:57+00:00","og_image":[{"width":724,"height":418,"url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg","type":"image\/jpeg"}],"author":"Anders S\u00f8ndergaard","twitter_card":"summary_large_image","twitter_creator":"@KapitalPartner","twitter_site":"@KapitalPartner","twitter_misc":{"Written by":"Anders S\u00f8ndergaard","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/kapitalpartner.dk\/en\/biosergen-skyrockets-145-and-virogates-enters-into-distribution-agreement\/#article","isPartOf":{"@id":"https:\/\/kapitalpartner.dk\/en\/biosergen-skyrockets-145-and-virogates-enters-into-distribution-agreement\/"},"author":{"name":"Anders S\u00f8ndergaard","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed"},"headline":"Biosergen skyrockets 145% and ViroGates enters into distribution agreement","datePublished":"2024-10-21T10:03:00+00:00","dateModified":"2024-10-24T10:03:57+00:00","mainEntityOfPage":{"@id":"https:\/\/kapitalpartner.dk\/en\/biosergen-skyrockets-145-and-virogates-enters-into-distribution-agreement\/"},"wordCount":882,"publisher":{"@id":"https:\/\/kapitalpartner.dk\/#organization"},"image":{"@id":"https:\/\/kapitalpartner.dk\/en\/biosergen-skyrockets-145-and-virogates-enters-into-distribution-agreement\/#primaryimage"},"thumbnailUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg","articleSection":["All investment Cases","Investeringscases","Investment cases","News","Sector cases"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/kapitalpartner.dk\/en\/biosergen-skyrockets-145-and-virogates-enters-into-distribution-agreement\/","url":"https:\/\/kapitalpartner.dk\/en\/biosergen-skyrockets-145-and-virogates-enters-into-distribution-agreement\/","name":"Biosergen skyrockets 145% and ViroGates enters into distribution agreement | Kapital Partner A\/S","isPartOf":{"@id":"https:\/\/kapitalpartner.dk\/#website"},"primaryImageOfPage":{"@id":"https:\/\/kapitalpartner.dk\/en\/biosergen-skyrockets-145-and-virogates-enters-into-distribution-agreement\/#primaryimage"},"image":{"@id":"https:\/\/kapitalpartner.dk\/en\/biosergen-skyrockets-145-and-virogates-enters-into-distribution-agreement\/#primaryimage"},"thumbnailUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg","datePublished":"2024-10-21T10:03:00+00:00","dateModified":"2024-10-24T10:03:57+00:00","breadcrumb":{"@id":"https:\/\/kapitalpartner.dk\/en\/biosergen-skyrockets-145-and-virogates-enters-into-distribution-agreement\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/kapitalpartner.dk\/en\/biosergen-skyrockets-145-and-virogates-enters-into-distribution-agreement\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/en\/biosergen-skyrockets-145-and-virogates-enters-into-distribution-agreement\/#primaryimage","url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg","contentUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg","width":724,"height":418},{"@type":"BreadcrumbList","@id":"https:\/\/kapitalpartner.dk\/en\/biosergen-skyrockets-145-and-virogates-enters-into-distribution-agreement\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/kapitalpartner.dk\/en\/"},{"@type":"ListItem","position":2,"name":"All investment Cases","item":"https:\/\/kapitalpartner.dk\/en\/category\/investment-cases\/en-investeringscases\/"},{"@type":"ListItem","position":3,"name":"Biosergen skyrockets 145% and ViroGates enters into distribution agreement"}]},{"@type":"WebSite","@id":"https:\/\/kapitalpartner.dk\/#website","url":"https:\/\/kapitalpartner.dk\/","name":"Kapital Partner A\/S","description":"","publisher":{"@id":"https:\/\/kapitalpartner.dk\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/kapitalpartner.dk\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/kapitalpartner.dk\/#organization","name":"Kapital Partner A\/S","url":"https:\/\/kapitalpartner.dk\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/","url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png","contentUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png","width":496,"height":432,"caption":"Kapital Partner A\/S"},"image":{"@id":"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/kapitalpartner","https:\/\/x.com\/KapitalPartner","https:\/\/www.linkedin.com\/company\/10438322","https:\/\/www.youtube.com\/channel\/UCODuY5PE_fxmp2nSSsq3l3w"]},{"@type":"Person","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed","name":"Anders S\u00f8ndergaard","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g","caption":"Anders S\u00f8ndergaard"}}]}},"_links":{"self":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/44274"}],"collection":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/comments?post=44274"}],"version-history":[{"count":1,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/44274\/revisions"}],"predecessor-version":[{"id":44275,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/44274\/revisions\/44275"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/media\/43132"}],"wp:attachment":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/media?parent=44274"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/categories?post=44274"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/tags?post=44274"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}